Iqbal Gill is a chemist with twenty four years of experience in the natural products, pharmaceutical, biotechnology, fine chemical, materials and food industries. He began his undergraduate studies at St Catherine’s College, Oxford, and completed a BSc in Botany and Chemistry, an MSc in Biotechnology, and a PhD in Chemistry at the University of Reading. In his career, Iqbal has worked at companies including Firmenich, Roche, Bristol-Myers Squibb and Codexis on compound discovery, synthetic chemistry, route development and process R&D, and he is currently Director of R&D at a top-tier manufacturer of medical cannabinoids located in the SF Bay Area in California. Iqbal manages cGMP operations that produce, qualify and formulate hundreds of kilos of purified cannabinoids and other phytochemicals. He also oversees the isolation and characterization of rare and novel cannabinoids, terpenoids, phenolics and other natural products, and the application of modern high-throughput bio/chemical methods to cannabinoid drug modification, discovery and delivery. Iqbal is also working on developing targeted phytocannabinoid formulations for inflammatory skin diseases, acute/chronic injuries, inflammatory arthritis, and neuralgias and focal neuropathies, as well as anti-inflammatory and analgesic non-cannabinoid natural products that target CB receptors and TRP channels and/or attenuate the actions of phytocannabinoids. Iqbal consults on natural products and chemical process R&D, has acted as an expert reviewer for the AFRC, BBSRC, EPSRC, DTI, EU BIOTECH Council and other bodies, and has published extensively in the peer-reviewed chemical literature.